Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia

Area of Science:

• Immunology
• Cancer Biology
• Hematology

Background:

• T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) acts as a negative immunoregulator in anti-tumor responses.
• The specific role of the Galectin-9/Tim-3 signaling pathway in chronic lymphocytic leukemia (CLL) remains unclear.
• Understanding this pathway is crucial for developing novel immunotherapies for CLL.

Purpose of the Study:

• To investigate the role of the Galectin-9/Tim-3 signaling pathway in regulating CD4+ T cell subsets within CLL patients.
• To determine the correlation between Galectin-9 levels and specific T cell populations and cytokines in CLL.
• To assess the therapeutic potential of targeting the Galectin-9/Tim-3 pathway in CLL.

Main Methods:

• Flow cytometry was utilized to analyze T cell subsets (Treg, Th17, Th1) and Tim-3 expression on T cells from CLL patients.
• Quantification of cytokine levels (IL-10, IFN-γ, TNF-α) in patient serum and in vitro cell cultures.
• In vitro experiments involved blocking the Tim-3/Galectin-9 pathway and co-culturing T cells with CLL cells.

Main Results:

• CLL patients exhibited an increase in regulatory T (Treg) cells, leading to a Treg/Th17 imbalance.
• Tim-3 was overexpressed on Th1 and Treg cells; Galectin-9 and IL-10 levels were elevated, particularly in advanced Binet stages (B and C), while IFN-γ decreased.
• Blocking the Tim-3/Galectin-9 pathway reduced IL-10 and increased IFN-γ and TNF-α. Tim-3+ Tregs inhibited Th1-mediated CLL cell apoptosis.

Conclusions:

• Elevated Galectin-9/Tim-3 signaling in CLL is associated with disease progression and immune evasion.
• This pathway negatively regulates CD4+ T cells, suppressing Th1 effector function and promoting Treg-mediated immune escape.
• The Galectin-9/Tim-3 pathway represents a promising therapeutic target for immunotherapy in chronic lymphocytic leukemia.